RxSight, Inc. granted inducement stock options for 571,286 shares and restricted stock units (RSUs) for 2,312,138 shares to Aziz Mottiwala, the company's new President and CEO, as part of his employment commencement on July 24, 2026. The stock options have an exercise price of $5.19 per share, matching the closing price on the grant date, with vesting spread over four years. The RSUs vest over three years with milestones at one, two, and three years. These grants are part of RxSight's 2026 Inducement Equity Incentive Plan and comply with Nasdaq rules. This move aims to incentivize Mottiwala's leadership as RxSight continues to innovate in adjustable intraocular lens technology for cataract surgery patients.
CrowdStrike, a leading cybersecurity firm, has seen its stock price increase by 85% year-to-date, reaching a market cap over $220 billion. Investment firm Cowen & Co. reiterated a "Buy" rating and raised the price target to $235, citing strong financ...
Dan Loeb's Third Point fund opened a new $533 million stake in Warner Bros. Discovery (WBD) in Q2 2026, joined by David Einhorn and George Soros also buying shares. This rare alignment among activist, value, and macro investors highlights interest in...
Broadcom shares have dropped to $392.99, about 34% below the average analyst price target of $527.88, despite posting strong AI semiconductor revenue growth of 143% year-over-year and a bullish outlook for continued AI demand. The company leads in cu...
Nvidia announced it will provide credit and computing power for OpenAI's new AI data center in Pike City, Ohio, supporting an initial 4.25 gigawatts of capacity with an option for 3.75 more. The data center, managed by SB Energy under a 20-year lease...
In Q2 2026, David Tepper's Appaloosa Management reduced holdings in memory chip makers like Micron and exited SanDisk, reallocating capital into AI-related stocks such as Amazon, Taiwan Semiconductor, NVIDIA, and a new position in CoreWeave. Notably,...
